Sinopharm Group Statistics

Total Valuation

Sinopharm Group has a market cap or net worth of EUR 6.33 billion. The enterprise value is 15.93 billion.

Market Cap	6.33B
Enterprise Value	15.93B

Important Dates

The next estimated earnings date is Thursday, August 28, 2025.

Earnings Date	Aug 28, 2025
Ex-Dividend Date	Jun 16, 2025

Share Statistics

Current Share Class	1.34B
Shares Outstanding	n/a
Shares Change (YoY)	+0.35%
Shares Change (QoQ)	-0.66%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.34B

Valuation Ratios

The trailing PE ratio is 7.01 and the forward PE ratio is 6.77.

PE Ratio	7.01
Forward PE	6.77
PS Ratio	0.09
PB Ratio	0.38
P/TBV Ratio	0.71
P/FCF Ratio	2.12
P/OCF Ratio	2.01
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.84, with an EV/FCF ratio of 5.33.

EV / Earnings	17.63
EV / Sales	0.24
EV / EBITDA	5.84
EV / EBIT	7.26
EV / FCF	5.33

Financial Position

The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.61.

Current Ratio	1.34
Quick Ratio	1.07
Debt / Equity	0.61
Debt / EBITDA	3.56
Debt / FCF	3.37
Interest Coverage	6.65

Financial Efficiency

Return on equity (ROE) is 8.24% and return on invested capital (ROIC) is 5.47%.

Return on Equity (ROE)	8.24%
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	5.47%
Return on Capital Employed (ROCE)	12.48%
Revenue Per Employee	682,055
Profits Per Employee	8,349
Employee Count	108,217
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Sinopharm Group has paid 451.45 million in taxes.

Income Tax	451.45M
Effective Tax Rate	25.62%

Stock Price Statistics

The stock price has decreased by -19.96% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-19.96%
50-Day Moving Average	2.06
200-Day Moving Average	2.29
Relative Strength Index (RSI)	43.20
Average Volume (20 Days)	2,044

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sinopharm Group had revenue of EUR 73.81 billion and earned 903.53 million in profits. Earnings per share was 0.29.

Revenue	73.81B
Gross Profit	5.55B
Operating Income	2.24B
Pretax Income	1.76B
Net Income	903.53M
EBITDA	2.52B
EBIT	2.24B
Earnings Per Share (EPS)	0.29

Full Income Statement

Balance Sheet

The company has 5.78 billion in cash and 10.06 billion in debt, giving a net cash position of -4.27 billion.

Cash & Cash Equivalents	5.78B
Total Debt	10.06B
Net Cash	-4.27B
Net Cash Per Share	n/a
Equity (Book Value)	16.47B
Book Value Per Share	3.29
Working Capital	12.02B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.16 billion and capital expenditures -168.25 million, giving a free cash flow of 2.99 billion.

Operating Cash Flow	3.16B
Capital Expenditures	-168.25M
Free Cash Flow	2.99B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 7.53%, with operating and profit margins of 3.04% and 1.22%.

Gross Margin	7.53%
Operating Margin	3.04%
Pretax Margin	2.39%
Profit Margin	1.22%
EBITDA Margin	3.41%
EBIT Margin	3.04%
FCF Margin	4.05%

Dividends & Yields

This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 4.02%.

Dividend Per Share	0.08
Dividend Yield	4.02%
Dividend Growth (YoY)	-28.81%
Years of Dividend Growth	4
Payout Ratio	29.23%
Buyback Yield	-0.35%
Shareholder Yield	3.67%
Earnings Yield	14.26%
FCF Yield	47.17%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sinopharm Group has an Altman Z-Score of 2.12 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.12
Piotroski F-Score	3